The project of a vast campus dedicated to cancer research and care has been decided by the President de la République Française after the catastrophic blast of the AZF chemical factory on the 21st of September 2001 in Toulouse (31 people killed, 2 500 injured, considerable damages).
The “Oncopole of Toulouse” now gathers academic, scientific, medical, clinical, technological and pharmaceutical research on cancer on a 220-hectare site next to the Toulouse airport, highways, hospitals and University. Its missions are to improve fundamental knowledge on all aspects of cancer biology and to provide patients with rapid access to innovative and individualized treatments. This project is strongly supported at the regional and national levels by the French Ministry of Health, Ministry of Education and Scientific Research, the Région Midi-Pyrénées and the City of Toulouse. Several actors compose this unique site in Europe:
- The Cancer Research Center of Toulouse (CRCT), a public research laboratory supported by Inserm, University Toulouse III-Paul Sabatier and CNRS
- The Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), a cancer care center directly connected to the CRCT, gathering several medical services from the University Hospital (CHU) of Toulouse and from the Institut Cladius Regaud (Centre de Lutte Contre le Cancer)
- The Institute of Advanced Technologies for life Sciences (ITAV), a public research laboratory supported by CNRS, INSA and University Toulouse III-Paul Sabatier
- The Etablissements Français du Sang (EFS), the national civil operator of blood transfusion in France
- Several labs from pharmaceutical and biotech companies (Pierre Fabre, Sanofi, Cyclopharma, start-ups...), etc...